Amarin Corp Plc (AMRN)

[Whalatane]

Concapak well this may surprise you but I largely agree with your post

I was on max statin therapy long before there was a CV Outcome Trial to prove benefit from statin .
Yes Statins reduced LDL and most THOUGHT that it would also reduce CV events ...so we took it in the hope it would .

I feel the same way about ADCOM and Vascepa .

I think V should have been approved at Adcom for the patient population at risk ...and then authorization recinded if R-IT does not show benefit .

If R-IT shows at least 20% RRR then you have to wonder how many patients and familes could have avoided CV events and strokes , if V had been approved for the Anchor indication.
JMO
Kiwi